Navigation Links
Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
Date:11/3/2010

This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
2. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
3. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
4. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
5. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
6. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
7. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
8. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
9. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
10. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
11. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LayerBio is an MIT spin-off developing ... The National Eye Institute (NEI) at the National Institutes ... SBIR grant to develop a drug-eluting intraocular lens (IOL) ... cause of vision loss in people over age 40 ... Dr. Ken Mandell, LayerBio’s Founder and CEO, "There is ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... to the rising ageing population and technological innovations ... and nutraceutical industries are catalysing the growth of ... @ http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report ... as well as new entrants/smaller firms to gauge ...
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... N.J., Jan. 11 A new blood test that identifies ... in the U.S. through Quest Diagnostics Incorporated (NYSE: ... is designed to aid the detection of colorectal cancer, the ... test is based on DNA methylation of the Septin9 gene, ...
... , , , , ... Cooperation With Diabetes Leader Novo Nordisk, - Important ... The Gerresheimer Group has set up a new ... commence operations early in,2010. On the basis of a long-term cooperation ...
... New chapter ... , ... -- The Society for Clinical Data Management recently published Edit Check Design Principles, a collection ... and data quality., , ,The chapter is a new addition to SCDM’s Good Clinical ...
Cached Biology Technology:Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection 2Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection 3Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil 2SCDM Releases Best Practices for Automated Data Cleaning 2
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Imagine that the players on your favourite football team ... helmets or pads. Left defenseless, they would become easy prey ... have left small water organisms vulnerable to their predators, which ... study. "At low calcium levels the organisms grow slower ...
... release as much as 1 billion tons of carbon emissions ... reported, according to a new Duke led study. Published ... provides the most comprehensive estimate of global carbon emissions from ... 1.2 billion tons. It suggests there is a high value ...
... study led by MIT neuroscientists has found that brain ... predict whether they will benefit from cognitive behavioral therapy. ... behavioral therapy or medications. However, it is currently impossible ... particular patient. The team of researchers from MIT, Boston ...
Cached Biology News:Changes in water chemistry leave lake critters defenseless 2Destroyed coastal habitats produce significant greenhouse gas 2Predicting how patients respond to therapy 2Predicting how patients respond to therapy 3
... flexible quadrupole MS detector optimized for HPLC ... and 2-D LC, as well as capillary ... drying gas system to create a finer ... low-to-medium polarity compounds, while providing for high ...
... is the ideal CO2 incubator for cell ... or embryos at or near body temperature. ... everything needed to protect and grow your ... stable incubation conditions ensure optimum culture growth. ...
... single-stranded DNA and RNA endonucleolytically to ... (DNA:DNA, DNA:RNA or RNA:RNA) are resistant ... concentrations of enzyme (1). The enzyme ... from double-stranded DNA (2), for selective ...
... DNA Ligation Kit enables ligation ... fragments in just 5 min ... on the DNA concentration, either ... concatemeric (high DNA concentration) ligation ...
Biology Products: